Skip to content
Back to search results

Clarke Hypoglycemia Awareness Questionnaire

Introduced by
William L. Clarke, Don J. Cox, Lois A. Gonder-Frederick
Year
1995
Type
Patient self-report questionnaire
Family
Hypoglycemia-specific awareness and symptom detection
Font size

What does it do?

The Clarke Hypoglycemia Awareness Questionnaire is an 8-item instrument designed to identify patients with impaired hypoglycemia awareness—a condition in which diabetic patients fail to perceive early warning symptoms of low blood glucose, substantially increasing their risk of severe hypoglycemia.

Developed by Clarke and colleagues in 1995, it is the most widely used screening tool for this dangerous complication in type 1 diabetes and in insulin-treated type 2 diabetes populations.

The intuition behind the method

In healthy glucose regulation, low blood glucose triggers sympathetic nervous system activation (adrenaline release), producing warning symptoms: shakiness, sweating, palpitations, tremor, and anxiety. These symptoms alert the patient to consume carbohydrate quickly. However, prolonged diabetes, intensive insulin therapy, or recurrent hypoglycemic episodes can blunt this symptom response, a phenomenon called hypoglycemia-associated autonomic failure (HAAF) or hypoglycemia unawareness. Patients with impaired awareness may experience severe hypoglycemia (seizure, loss of consciousness) without warning, creating life-threatening risk. The Clarke questionnaire rapidly screens for this condition, enabling identification of high-risk patients warranting intensive glucose monitoring and targeted interventions.

History

Developed 1995 by Clarke, Cox, and Gonder-Frederick (University of Virginia, Charlottesville) published in Diabetes Care 18(6):517-522. Initial validation in 150 type 1 diabetes patients with prospective monitoring of hypoglycemic episodes and symptoms; identified 8-item subset with high sensitivity and specificity for impaired awareness. Recognized pivotal study establishing hypoglycemia awareness as a clinical syndrome and the questionnaire as standard screening tool. Subsequently validated in >10,000 patients across diverse populations (pediatric, adult, pregnant women); recommended by major diabetes organizations by 1997. Adapted into 20+ languages. Newer versions (CLARK-DES, Hypoglycemia Unawareness Risk Assessment) incorporate additional severity grading but Clarke-8 remains the most widely recognized. Recent digital adaptations enable continuous monitoring and real-time risk stratification when combined with glucose data.

When to use it

The Clarke HAQ is indicated for: (1) Routine screening in all type 1 diabetes patients at initial endocrinology visit and periodically (annually or biannually) thereafter; (2) Insulin-treated type 2 diabetes patients, particularly those on intensive regimens; (3) Evaluation of patients with unexplained severe hypoglycemia episodes or frequent nocturnal hypoglycemia; (4) Identification of candidates for continuous glucose monitoring technology and insulin pump therapy; (5) Research studies investigating hypoglycemia awareness, risk factors for HAAF, and interventions to restore awareness. Increasingly integrated into diabetes management algorithms and clinic decision-support systems.

Limitations and considerations

  • Subjective recall: Relies on patient memory of recent hypoglycemic episodes; patients with infrequent hypoglycemia may have limited recent experience to report, introducing uncertainty.
  • Symptom heterogeneity: Individual patients vary in which symptoms predominate (some experience primarily adrenergic symptoms like tremor; others experience neuroglycopenic symptoms like confusion); questionnaire equally weights all symptom types.
  • Cognitive capture: Patients may overestimate or underestimate symptom recognition; cognitive biases (optimism bias, anchoring to recent severe episode) can distort responses.
  • Imperfect correlation with objective hypoglycemia frequency: Some patients report impaired awareness but experience relatively few asymptomatic lows on CGM; others report preserved awareness but have frequent hypoglycemic episodes without symptoms—actual measurement-based categorization occasionally conflicts with self-reported awareness.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Rapid screening: 8 items require <5 minutes; feasible for routine clinical use during standard diabetes visits without additional staff or equipment burden.
  • Strong prognostic value: Impaired awareness score strongly predicts subsequent severe hypoglycemia risk; discriminates high-risk from low-risk patients with sensitivity ~75-85% and specificity ~70-80%.
  • Clinical actionability: Clearly identifies patients who warrant intensive glucose monitoring (CGM), technology interventions (insulin pumps), or behavioral interventions (hypoglycemia avoidance training).
  • Universally adopted: Recommended by American Diabetes Association, European Association for the Study of Diabetes, and Endocrine Society; standardized across international diabetes programs.

Applications

  • Diabetes clinic screening: Annual or biennial administration to identify new or worsening hypoglycemia awareness impairment; flags patients for intensive monitoring and technology provision.
  • Continuous glucose monitoring (CGM) candidacy assessment: Impaired awareness (score ≤3) is a primary indication for CGM initiation in most diabetes programs; questionnaire results integrated into reimbursement authorization.
  • Insulin pump therapy planning: Patients with impaired awareness combined with elevated severe hypoglycemia frequency are candidates for closed-loop insulin pumps with hypoglycemia suspension features; questionnaire identifies this population.
  • Driving safety evaluation: Impaired hypoglycemia awareness is a risk factor for hypoglycemia-related motor vehicle accidents; questionnaire results inform driving counseling, licensing recommendations, and occupational fitness assessment.
  • Research outcome: Primary or secondary measure in studies evaluating hypoglycemia awareness restoration (pancreatic islet transplantation, insulin pump therapy, behavioral training); responsiveness to interventions demonstrated.

How it works

How it works

1

The 8-item questionnaire asks patients to reflect on their recent hypoglycemic episodes (past 12-24 months) and describe their typical symptom experience. Items address: (1) How often hypoglycemia is experienced, (2) Perception of impending hypoglycemia before blood glucose measurement, (3) Sweating as early symptom, (4) Trembling as early symptom, (5) Palpitations as early symptom, (6) Nervousness/anxiety as early symptom, (7) Hunger as early symptom, (8) Tingling lips/mouth as early symptom. Responses are typically yes/no or frequency-based (rarely, sometimes, often). Administration: 3-5 minutes, self-administered or during clinical interview. Suitable for all ages 8+ (pediatric version available); requires understanding of hypoglycemia experience.

Formula
Patient responds to 8-item questionnaire about hypoglycemia symptom recognition and warning time
2

Raw awareness score calculated by summing responses to specific items (exact algorithm varies; most common uses 0-7 point scale with higher scores indicating better awareness). Standard clinical threshold: Score ≤3 = impaired awareness; Score 4-7 = normal/preserved awareness. Alternative scoring: Categorical classification (normal awareness, early warning loss, hypoglycemia unawareness). No subscales; single summary score. Original publication by Clarke et al. reported 1 point for each symptom the patient recognizes as an early warning; ≤4 symptoms = impaired awareness. Concordance with objective measures (frequency of biochemically-documented asymptomatic hypoglycemia on continuous glucose monitoring) typically 70-80%.

Formula
Calculate awareness score (0-7) and symptom recognition categories; classify as normal or impaired awareness
3

Scores ≤3 (impaired awareness) indicate the patient has significantly reduced ability to recognize hypoglycemic warning symptoms and is at substantially elevated risk for severe hypoglycemia (seizure, loss of consciousness, accidents while driving or operating machinery). Clinical action: Refer patients with impaired awareness to endocrinologist; consider continuous glucose monitoring (CGM) with low glucose alerts, insulin pump therapy with automated suspension features, or structured hypoglycemia avoidance training. Preserved awareness (score 4-7) does not guarantee safety; baseline assessment combined with periodic rescreening and objective glucose monitoring recommended. Score changes over time (deterioration of awareness with progressive diabetes duration or intensive therapy) require intervention adjustment.

Formula
Score ≤3 indicates impaired hypoglycemia awareness; higher scores indicate preserved awareness and earlier symptom detection

Frequently asked questions

What score is safe to drive with?

No absolute safe threshold. Preserved awareness (score ≥4) does not guarantee driving safety; impaired awareness (score ≤3) substantially elevates risk. Combined assessment using Clarke HAQ, documented hypoglycemia frequency (from glucose logs or CGM), and patient's glycemic target all inform clinical driving counseling. Recommendations vary by jurisdiction; some require CGM for impaired-awareness patients operating vehicles. Discuss risk with patients and consider referral to occupational health.

Can hypoglycemia awareness be restored?

Yes, partially. Strict hypoglycemia avoidance for 2-6 weeks can restore some symptom recognition in mild impairment, though complete restoration is uncommon in patients with long disease duration or after multiple hypoglycemic episodes. Newer interventions (hybrid closed-loop insulin pumps, islet transplantation, sympathomimetic agents) show promise but are not standard care. CGM enables safe living with impaired awareness by providing automated low glucose alerts.

Should the questionnaire be repeated if score is normal?

Yes. Recommended rescreening every 1-2 years; more frequent (6-12 months) if multiple risk factors for HAAF (long duration, intensive therapy, frequent hypoglycemia episodes). Awareness can deteriorate over time; periodic screening detects early changes warranting intervention.

Does the score predict future severe hypoglycemia risk numerically?

Impaired awareness (score ≤3) is associated with 3-5 fold increased risk of severe hypoglycemia compared to preserved awareness; however, individual risk varies widely based on glycemic control, hypoglycemia frequency, and behavioral factors. The questionnaire is a categorical screener (high vs. low risk), not a precise numerator of risk. Objective glucose monitoring provides more granular risk prediction.

Related methods

Sources

  1. Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995). Reduced awareness of hypoglycemia in adults with IDDM: A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care, 18(6), 517-522.

    Open DOI reference
    Copied.
  2. Gold, A. E., MacLeod, K. M., Frier, B. M., et al. (2012). Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care, 17(9), 697-703.

    Open publication reference
    Copied.